NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have been given an average rating of “Moderate Buy” by the five ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $8.50.

Several equities research analysts have weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Friday, May 8th. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th.

Insiders Place Their Bets

In other NeuroSense Therapeutics news, CFO Or Eisenberg bought 250,000 shares of NeuroSense Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average cost of $0.80 per share, with a total value of $200,000.00. Following the transaction, the chief financial officer directly owned 1,504,050 shares of the company’s stock, valued at approximately $1,203,240. This represents a 19.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Alon Ben-Noon purchased 250,000 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at $3,627,386.40. The trade was a 5.84% increase in their position. The disclosure for this purchase is available in the SEC filing. 27.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On NeuroSense Therapeutics

A number of large investors have recently modified their holdings of the business. Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics in the 4th quarter valued at approximately $77,000. Squarepoint Ops LLC grew its position in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the last quarter. Jane Street Group LLC acquired a new position in NeuroSense Therapeutics during the 2nd quarter valued at approximately $54,000. Finally, Two Sigma Investments LP acquired a new position in NeuroSense Therapeutics during the 3rd quarter valued at approximately $26,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Stock Performance

NASDAQ:NRSN opened at $0.73 on Monday. The company’s 50-day simple moving average is $0.78 and its 200-day simple moving average is $0.83. NeuroSense Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $2.14. The stock has a market capitalization of $23.72 million, a P/E ratio of -1.35 and a beta of 1.58.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.